David Hutton

Ocuphire Pharma has completed enrollment in the VEGA-1 Phase 2 clinical trial evaluating the safety and efficacy of drops to treat presbyopia.

Ophthalmologists at New York Eye and Ear Infirmary of Mount Sinai have created a new technique to evaluate patients with sickle cell retinopathy and assess the disease before it progresses and leads to permanent vision loss.

In an announcement that could impact ophthalmologists, the Department of Health and Human Services’ Office for Civil Rights revealed this week that it will enforce a prohibition of discrimination on the basis of sexual orientation and gender identity.

Graybug Vision’s Phase 2b ALTISSIMO trial of GB-102 focuses on the treatment of wet age-related macular degeneration.

Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).

Mohamed Abou Shousha, MD, PhD, and Richard Parrish II, MD, discuss their ARVO 2021 presentation regarding a study analyzing visual field measurements using the Heru Visual Field Multi-platform application downloaded on two different commercially available augmented reality devices.

Ocular Innovations debuts an option that delivers content touchpoints through a frictionless mobile experience.

Tarsus Pharmaceuticals kicks off Saturn-2, trial, which is designed similar to Saturn-1, first pivotal trial for TP-03. Topline data from Saturn-1 is expected in July.

According to Applied Genetic Technologies Corp., groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials.

Theodore Leng, MD, discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," during the virtual 2021 ARVO meeting.

Michael Mbagwu, MD, speaks on the highlights of his virtual 2021 ARVO presentation regarding the development of an algorithm tool that links patient imaging to their clinical data, specifically within the AAO IRIS Registry.

Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.

According to Sandoz, it will begin enrolling the first patients in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study.

Glenn J. Jaffe, MD, discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.

Seth Miller, clinical operations manager at Ora Inc., discusses the relationship between the symptoms of dry eye and aging, based on his ARVO 2021 presentation.

After more than a decade at the helm of the American Academy of Ophthalmology as its CEO, David W. Parke II, MD, has announced that he will be stepping down from the position.

After receiving FDA approval for its IPL device, Lumenis Ltd. announced that it is launching OptiLight, a bright solution for dry eyes.

ThermaMEDx has unveiled a self-heating, pre-moistened, disposable, sterile cleaning eye-pad for use in treating the symptoms of dry eyes and meibomian gland dysfunction.

The National Institute of Health has supported early testing of the artificial retina. Now, scientists are testing whether manufacturing it on the International Space Station results in a viable treatment for people with blinding eye diseases.

‘Revolutionary Eye and Vision Research’ theme of annual meeting.

In an update, the CDC noted that the chances of an individual contracting COVID-19 from surface transmission is low.

Santen, Massachusetts Eye and Ear, Ulster University researchers will focus on ways to preserve vision by slowing, reversing, or preventing the damage.

Ocuphire Pharma’s ZETA-1 trial will investigate the potential of APX3330 to offer an oral treatment for diabetic retinopathy.

According to Verizon Business, BlueJeans Telehealth is way for providers and patients to conduct data-driven virtual care conversations.

During the trial, a patient gained vision, which lasted more than a year, after a single injection of an experimental RNA therapy into the eye.

Doug Mastel, who founded Mastel Precision Surgical Instruments Inc., passed away on March 20. He was 67.

A decision to stop the trial is based on results of a pre-planned interim sample size analysis conducted by an independent committee.

Ophthalmologists share the most pressing issues on their mind within the glaucoma space — and why losing sleep from time to time may actually be a good thing.

ProQR Therapeutics has unveiled the results from its Phase 1/2 Stellar trial examining QR-421a n patients with Usher syndrome and non-syndromic retinitis pigmentosa.

A clinical trial of NCX 470 will evaluate the drug for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.